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Anti-Tac(Fv)-PE40 is a chimeric single chain im- 
munotoxin in which anti-Tat variable heavy and light 
chains held together by a peptide linker are attached 
to PE40, a truncated form of Pseudomonas exotoxin. 
This molecule was shown to be extremely cytotoxic for 
interleukin 2 (IL2) receptor bearing cells in tissue 
culture (Chaudhary, V. K., Queen, C., Junghans, R. P., 
Waldmann, T. A., FitzGerald, D. J., and Pastan, I. 
(1989) Nature 339, 394-397). Here we describe var- 
ious forms of anti-Tac(Fv)-PE40 protein in which the 
order of the variable domains of anti-Tat has been 
switched and also three different types of peptide link- 
ers have been used. All these proteins were purified to 
near homogeneity and were found to have similar cy- 
totoxic activities against various human cells express- 
ing the p55 subunit of the IL2 receptor. Anti-Tsc(Fv)- 
PE40 was also found to have a very potent suppressive 
activity against phytohemagglutinin-activated human 
lymphoblasts and in a human mixed lymphocyte reac- 
tion. Anti-Tac(Fv)-PE40 appeared in the blood rapidly 
in mice after intraperitoneal administration and could 
be detected in the blood for up to 8 h. Anti-Tac(Fv)- 
PE40 warrants evaluation as an anti-tumor and im- 
munosuppressive agent in humans. 
Immunotoxins are emerging as potential chemotherapeutic 
agents for the treatment of cancer, acquired immune deli- 
ciency syndrome, and immunological disorders (1, 2). Several 
different toxins have been employed to make immunotoxins. 
These include ricin, diphtheria toxin, Pseudomonas exotoxin, 
modecin, and saporin. We have been constructing immuno- 
toxins using Pseudomonas exotoxin (PE).’ PE is composed of 
three major structural domains each with a different function. 
Domain I is responsible for cell recognition, domain II for 
translocation across the cell membrane, and domain III for 
the ADP-ribosylation activity of the toxin, although recently 
the last five amino acids of the carboxyl end of domain III 
have also been shown to have a role in translocation (3-5). 
Immunotoxins are conventionally made by coupling mono- 
clonal antibodies to toxins using chemical cross-linkers. Re- 
cently, it has been possible to produce immunotoxins in 
Escherichia coli by fusing DNA segments encoding the Fv 
* The costs of publication of this article were defrayed in part by 
the payment of page charges. This article must therefore be hereby 
marked “advertisement” in accordance with 18 U.S.C. Section 1734 
solely to indicate this fact. 
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region; kb, kilobase( SDS, sodium dodecyl sulfate; PAGE, poly- 
acrylamide gel electrophoresis; PHA, phytohemagglutinin. 
regions of antibodies to a truncated form of the toxin, thereby 
producing single chain antibody toxin fusion proteins (6, 7). 
We initially produced a molecule termed anti-Tac(Fv)-PE40 
in which the variable region of the heavy chain of the anti- 
Tat antibody is attached through a peptide linker to the 
variable light chain which in turn is fused to PE40 (6). The 
latter is a truncated form of Pseudomonas exotoxin which 
lacks the binding domain of the toxin. Anti-Tac(Fv)-PE40 is 
cytotoxic to cells expressing the p55 subunit of the human 
IL2 receptor (6). 
The affinity of anti-Tac(Fv)-PE40 for the ~55 subunit of 
the IL2 receptor was found to be very close to that of native 
anti-Tat (6). To study the structural requirements for binding 
and to explore the possibility of creating a more active mole- 
cule, we have made several different anti-Tac(Fv)-PE40 con- 
structions. In these, the order of the variable heavy and light 
chains has been switched and the role of the peptide linker 
joining the variable chains has been explored by using three 
different linkers. In addition, the activity of anti-Tac(Fv)- 
PE40 was assessed on various types of normal and malignant 
human T cells. The cytotoxicity was compared with that of 
two other chimeric toxins composed of IL2 linked to different 
mutant forms of PE. Anti-Tac(Fv)-PE40 was found to be 
more active than either IL2-PE40 or IL2-PE664G’” (8,9), two 
other chimeric toxins directed at IL2 receptor-bearing cells. 
MATERIALS AND METHODS 
Construction of Plasmids-Polymerase chain reaction-based meth- 
ods were used to amplify, create cloning sites, and assemble the 
plasmids containing the variable domains of the light and the heavy 
chains of anti-Tat joined together by a peptide linker. These variable 
domains are fused to DNA sequences encoding PE40. These fusion 
genes are under the control of a T7 promoter and an appropriate 
ribosome binding site has been included. 
p7018-Fig. 1 summarizes the cloning strategy employed for this 
construction. The starting template material was cDNA of the light 
and heavy chain of anti-Tat cloned as an EcoRI insert in pUC18. 
Oligonucleotides VK73 and VK74 were used to amplify the variable 
domain of the heavy chain (V,) using anti-Tat heavy chain cDNA as 
template. VK75 and VK76 were used to amplify the variable domain 
of the light chain (V,) using the anti-Tat light chain cDNA as 
template. The conditions of the polymerase chain reaction have been 
described previously (7). For VK73, 23 nucleotides at the 3’-end were 
the same as the 5’-sequence of the cDNA encoding the mature heavy 
chain of anti-Tat. VK73 also introduced an NdeI site and an initiation 
methionine at the 5’-end. The 3’-end of the oligonucleotide, VK74, 
was complementary to the 3’-end of the variable domain of the heavy 
chain. VK74 also encoded the first 8 anticodons of the peptide linker 
followed by a KpnI site, and the nucleotides at its 5’-end were 
comnlementarv to the sequences in the CHl domain. VK75 carried 
nucieotides fo; a KpnI scte and for the last 8 codons of a peptide 
linker. The last 23 nucleotides of VK75, at the 3’-end, were the same 
as that of the 5’-end of the mature light chain. The 3’-end of 
oligonucleotide VK76 contained 24 nucleotides which were comple- 
mentary to the 3’-end of the variable domain of the light chain, 
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followed by nucleotides for a Hind111 site. The 5’-end of VK76 was 
complementary to the constant domain of the K light chain. 
The amplified DNA containing Vn was digested with NdeI and 
KpnI, while that containing Vi. was digested with KpnI and HindIII. 
The digested fragments were purified on 1.8% low melting point 
agarose (Sea Plaque GTG agarose, FMC). Separately, plasmid pVC20 
was digested with NdeI and Hind111 and dephosphorylated. pVC20 
encodes a PE derivative of 43 kDa termed PE43 (10). A three fragment 
in-gel ligation was set up using two polymerase chain reaction- 
amplified, enzyme-digested fragments containing Vn and VL with a 
3.75-kb fragment of pVC20 carrying PE43 and promoter sequences. 
Correct clones were identified by restriction enzyme analysis. One of 
the right clones, pVC701, was digested with KpnI followed by T4 
DNA polymerase to remove the 4-base overhang and ligated. The 
clones were screened for the loss of the KpnI site. These clones 
(pVC701020) produced a protein of approximately 66 kDa reacting 
with antibodies to PE. pVC701020 was digested with Hind111 and 
BamHI and dephosphorylated. Separately, pVC38H (7) was digested 
with Hind111 and BamHI to isolate an 0.8-kb fragment which was 
ligated with the HindIII- and BumHI-restricted 2.9-kb fragment of 
pVC701020. The resulting clones contained Vn, linker Ll, VL, and 
DNA sequences for PE40 under the control of a T7 promoter (Fig. 
2). The clones were checked by restriction enzyme digestions and, 
finally, by protein expression. One of the correct clones, ~7018, which 
expressed a 63-kDa protein reactive with the antibodies to PE, was 
selected for large scale expression and purification of the protein. 
p70528-This plasmid was constructed using a similar strategy as 
used for ~7018, except that the oligonucleotide primers were different. 
In this plasmid, VL is linked to the Vu through a 15-amino acid 
peptide linker Ll, and Vn is linked to PE40 (Fig. 2). Accordingly, 
oligonucleotides VK77 and VK78 were used to amplify VL. These 
oligonucleotides introduced an NdeI site, initiator methionine at the 
.!I’-end, the first 7 codons of the peptide linker, and a KpnI site at 3’. 
end. VK79 and VK89 introduced a KpnI site, the last 8 codons of the 
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peptide linker at the 5’-end of Vn, and a Hind111 site at the 3’-end of 
Vn. Other steps were the same as described above for the construction 
of p7018. 
p70538-This plasmid is similar to ~70528 but contains a 16-amino 
acid peptide linker termed L2 which has a different amino acid 
composition (Fig. 2). ~70538 was derived from ~70528 using two 
oligonucleotides, VK93 and VK89. The 5’-end of the VK93 is the 
same as the J region of Vt in ~70538 followed by codons for the new 
peptide linker, and the 3’-end is the same as the B/-end of the Vu. A 
polymerase chain reaction was set up with VK93 and VK89 using 
p7d528 as template. The amplified product was digested with Ssti 
and Hind111 and ligated with a 3.95-kb fragment of SstI-HindIII- 
digested/dephosphoiylated ~70528. The correct clones were identified 
by restriction enzyme digestion followed by expression of protein in 
BL21 (XDE3). 
p70548-This was created using a strategy identical with that 
described for ~70538 except using oligo VK94 and VK89, which 
introduced a 14.amino acid linker L3 (Fig. 2). 
The DNA sequences in the peptide linker region were confirmed 
by dideoxy sequencing. 
Expression and Purification of Proteins-To express and localize 
anti-Tac(Fv)-PE40, E. coli BL21 (XDE3) cells were transformed with 
the appropriate plasmids and cultured at 37 “C in super broth supple- 
mented with ampicillin (100 fig/ml). At an ODsso of 0.8, isopropyl-l- 
thio-B-D-galactopyranoside was added to a final concentration of 1 
mM, and the culture was further incubated for 90 min. Cells were 
harvested and protein was localized as described previously (11). The 
fusion proteins were mostly contained in the inclusion bodies so these 
were used as the source for further purification. Proteins were dena- 
tured in 7 M guanidine hydrochloride and renatured by rapid dilution 
in phosphate-buffered saline (12). The renatured protein was applied 
onto a fast protein liquid chromatography Mono Q lO/lO column in 
0.02 M Tris-HCl, pH 7.4, and eluted by a linear gradient of O-O.5 M 
NaCl in the same buffer. Fractions containing the fusion protein were 
detected by SDS/PAGE and cytotoxic activity on HUT102 cells, 
pooled, and concentrated. For further purification, chimeric protein 
was applied to a TSK 250 gel filtration column and fractions corre- 
sponding to the monomeric form were pooled, quantitated, and used 
for further characterization. 
Protein Synthesis Inhibition Assay-Cytotoxic activity of the fu- 
sion protein was determined by assaying the inhibition of protein 
synthesis on HUTIOZ, Cr11.2, MT-l, ELT5, and EL4J3.4. Cells were 
washed twice with RPM1 1640. mated in 24-well nlates. and incubated 
with several dilutions of the toxin for 16-20 h at 37 “C. Protein 
synthesis was assayed by labeling the cells with [:‘H]leucine for 90 
min and counting the trichloroacetic acid-precipitable protein as 
described (6). 
Determinations of Blood Level and Toxicity of Anti-Tac(Fv)-PE40 
in Mice-Anti-Tac(Fv)-PE40 was injected intraperitoneally into five 
groups of female BALB/c mice in doses ranging from 5-100 pg. 
Animals were observed for 72 h for signs of toxicity and death. LDso 
is the dose of toxin able to kill 50% of the animals in a group in 48 
h. For blood level analysis, female BALB/c mice were injected intra- 
peritoneally with 10 pg of the fusion protein 7018. Blood was drawn 
from the orbital vein at different times after injection, and the level 
of anti-Tac(Fv)-PE40 was assayed by incubating the serum with 
HUT102 cells and measuring inhibition of protein synthesis. A stand- 
ard curve made with pure anti-Tac(Fv)-PE40 on HUT102 cells was 
used to determine the concentration in the serum. 
Effect of Anti-Tac(Fv+PE40 on Human Lymphocytes-Peripheral 
blood mononuclear cells were prepared from the blood of normal 
volunteer donors using the Ficoll and sucrose density gradient cen- 
trifugation. For PHA stimulation, peripheral blood mononuclear cells 
were-cultured at a density of 5 -X io” cells/ml at 37 “C in 0.1% 
ohvtohemaaalutinin-P (PHA-P) for 3 davs. The culture was diluted 
i:iwith fresh medium, and human rIL2 was added to a concentration 
of 50 units/ml. The culture was further incubated for 1-2 days, cells 
were then harvested, washed, and resuspended at 8 x 10’ cells/ml in 
assay medium consisting of leucine-free Eagle’s minimal essential 
medium with 5% fetal bovine serum, 1 mM sodium pyruvate, 0.1 mM 
nonessential amino acids, 2 mM L-glutamine, 100 units/ml penicillin, 
100 fig/ml streptomycin, and 50 @g/ml gentamycin. For two-way 
mixed lymphocyte reaction, 60 ml of heparinized blood was collected 
from two individuals and peripheral blood mononuclear cells were 
isolated. 5 X lo6 cells from each individual were mixed in 10 ml of 
medium and incubated at 37 “C, rIL2 (50 units/ml) was added on day 
3, and the culture was further incubated for 3 days. Cells were 
harvested and resuspended in the assay medium as described above. 
To determine the effect of anti-Tac(Fv)-PE40, lymphoblasts were 
aliquoted into 96-well plates, and serial dilutions of the toxin were 
added along with rIL2 (IO units/ml). The culture was incubated for 
2 days at 37 “C, pulsed for 6 h with [“Hlleucine. Cells were harvested 
using a microplate harvester on glass fiber filters and counted. 
Other Methods-Protein was measured bv the method of Bradford 
using the Bio-Rad protein assay reagent. SDS/PAGE was done by 
using the method of Laemmli (13). 
RESULTS 
We have previously shown that a single chain anti-Tac(Fv)- 
PE40 molecule composed of the heavy and light chain variable 
regions of anti-Tat connected to PE40 makes a very active 
immunotoxin that inhibits protein synthesis in HUT102 cells 
with an IDso of -0.15 rig/ml (6). To determine if the structure 
of the recombinant immunotoxin could be altered and its 
activity retained or improved, we made several new construc- 
tions in which the order of the Vi. and Vu chains was reversed, 
or in which the amino acid sequence of the linking peptide 
was altered. The structures of these new constructions are 
illustrated in Fig. 2 and described under “Materials and Meth- 
ods.” All the chimeric proteins were expressed in E. coli using 
the T7 expression system, extracted from inclusion bodies by 
guanidine hydrochloride, and, after renaturation, purified to 
near homogeneity by successive ion exchange and size exclu- 
sion chromatography. In all cases, a highly purified chimeric 
toxin was obtained (Fig. 3), and the yields of toxin were 
approximately equal. 
The purified toxins were tested on several different cell 
lines. These included HUT102 and CrII.2 which contain both 
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FIG. 2. Expression vector for various anti-Tac(FvbPE40 
proteins. A, ~7018 showing the basic plasmid used for expression of 
the chimeric proteins. B, order of variable domains in various con- 
structions and linkers. V,, variable heavy; VL, variable light; L, linker; 
B, BamHI; A, AuaI; Amp, p-lactamase gene. 
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FIG. 3. SDS-PAGE of purified anti-Tac(Fv)-PE40 proteins. 
10% SDS-polyacrylamide gels were run and stained with Coomassie 
Blue. Lane I, 7018; lane 2, 70528; lane 3, 70538; lane 4, 70548. 
Molecular weight markers are shown X lo-“. 
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subunits of the human lL-2 receptor (~55 and p75), MT-1 
which contains only human ~55, ELT5 which has human ~55 
and mouse ~75, and EL4J3.4 which has mouse ~55 and ~75. 
As shown in Fig. 4 and Table I, all four chimeric toxins were 
very active in inhibiting protein synthesis in HUT102 cells 
with IDS0 values ranging from 0.10 to 0.15 rig/ml. The agents 
also had similar action against the other cell lines which 
contained the human ~55 subunit (CrII.2, MT-l, and ELT5) 
but not on cells containing the mouse p55 subunit reflecting 
the species specificity of the anti-Tat antibody. 
Effect of Anti-Tac(Fv)-PE40 on Human T Lymphoblast 
Proliferation-One possible use of anti-Tac(Fv)-PE40 is in 
the treatment of autoimmune diseases or allograft rejection. 
Therefore, we tested the activity of one of the recombinant 
immunotoxins on human lymphoblasts which were activated 
either by the mitogen, PHA, or in a mixed lymphocyte reac- 
tion. The stimulated lymphoblasts express functional IL2 
receptor on their surface. For this purpose, we used the protein 
encoded by plasmid ~7018 (Fig. 2). As shown in Table II, anti- 
Tac(Fv)-PE40 inhibited the protein synthesis of both PHA 
and mixed lymphocyte reaction-stimulated human lympho- 
blasts with IDso values of 0.13 rig/ml and 0.05 rig/ml, respec- 
tively. As a control, we tested the toxin on K562 cells which 
do not express the IL2 receptors and found that high levels 
of the toxin were required to intoxicate these cells. The 
activity of anti-Tac(Fv)-PE40 on activated T lymphoblasts 
was compared with IL2-PE40 and IL2-PE664G’“, chimeric 
toxins that also bind to the IL2 receptor. IL2-PE40, although 
previously shown to be very active against mouse splenocytes 
(14), had very little activity toward the human cells (Table 
II). IL2-PE664G’“, a chimeric toxin in which the ability of 
domain I to bind to the Pseudomonas exotoxin receptor has 
been inactivated by mutations at positions 57, 246, 247, and 
.01 .1 1 10 100 
Toxin, nglml 
FIG. 4. Cytotoxicity of various fusion proteins on HUT102 
cells. Cells were incubated with the respective toxin for 16-20 h and 
pulsed with [“HI leucine and protein synthesis is shown as percent of 
control where no toxin was added. 0, 7018; n , 70528; 0, 70538; and 
Q70548. 
TABLE I 
Cytotoricity of anti-Tac(Fv)-PE40 proteins on various 
IL2-receptor-bearing cells 
ID,, is the protein concentration required to inhibit protein syn- 
thesis by 50%. H, human; M, mouse. Other details are given under 
“Materials and Methods.” 
Subunit 
Cell line present 
IDSO 
p55 p75 7018 70528 70538 70548 
w/ml 
HUT102 H H 0.15 0.11 0.13 0.10 
Cr11.2 H H 1.7 1.1 1.8 1.6 
MT-1 H None 0.37 0.15 0.25 0.25 
ELT5 H M 0.56 0.32 0.54 0.45 
EL4J3.4 M M >l.OOO >l.OOO >l.OOO >l.OOO 
TABLE II 
Comparison of anti-Tac(Fv)-PE40, IL2-PE40, and IL2-PE66*“‘” for 
inhibition of human lymphoblast protein synthesis 
ID,, is the concentration of protein required to inhibit protein 
synthesis by 50%. K562 is an ILZ receptor-negative cell line. 
ID,0 
Activated T 
lvmohoblasts K562 
Experiment 1, PHA lymphoblasts 
Anti-Tac(Fv)-PE40 
IL2-PE40 
IL2-PE664G’” 
Experiment 2, PHA lymphoblasts 
Anti-Tac(Fv)-PE40 
IL2-PE40 
IL2-PE66”“‘” 
Experiment 3, MLR lymphoblasts 
Anti-Tac(Fv)-PE40 
IL2-PE40 
IL2-PE664G’” 
co.16 93 
380 345 
15 910 
0.13 91 
xl00 180 
72 1145 
0.05 
83 
12 
TABLE III 
Toxicity of anti-Tac(Fv)-PE40 in mice 
Female BALB/c mice were injected with a single indicated dose of 
the fusion protein. Number of deaths were recorded after 48 h of the 
toxin administration. 
Amount injected Number of deaths 
G&T 
5 O/3 
10 O/3 
25 213 
50 313 
100 3/3 
FIG. 5. Blood level of anti-Tac(Fv)-PE40. The experiment 
was performed as described under “Materials and Methods.” Results 
are average of two experiments. 
249, had more activity than IL2-PE40 against the activated 
human cells, but was nevertheless much less potent than anti- 
Tac(Fv)-PE40 (Table II). Clearly, anti-Tac(Fv)-PE40 was the 
most cytotoxic of the three molecules tested. 
Blood Level and Toxicity of Anti-Tac(Fv)-PE40 in Mice- 
The extremely potent in vitro cytotoxicity of anti-Tac(Fv)- 
PE40 on IL2 receptor-bearing cells makes it a promising 
molecule for testing in vivo against IL2 receptor-bearing tu- 
mors or for immunosuppression. Accordingly, various 
amounts of anti-Tac(Fv)-PE40 were given intraperitoneally 
to mice to assess its toxicity. The LDso of a single dose was 
found to be between 10 and 25 pg (Table III). To determine 
the blood level of anti-Tac(Fv)-PE40, BALB/c female mice 
were injected intraperitoneally with 10 pg of protein. Blood 
was drawn at various times after the injection and assayed on 
HUT102 cells for immunotoxin activity. A peak blood level 
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of 1.9 rg/ml was obtained 2 h after the injections (Fig. 5). 
Detectable levels of toxin were present for up to 8 h, but by 
12 h, toxin could no longer be found in the blood (Fig. 5). 
DISCUSSION 
We have shown that anti-Tac(Fv)-PE40, a single chain 
immunotoxin, is very active in killing cells bearing the human 
p55 subunit of the IL2 receptor. In this type of chimeric toxin, 
the variable regions of the heavy and light chain are held 
together by a linking peptide. We have utilized several differ- 
ent peptide linkers containing 14, 15, or 16 amino acids and 
found all of them to produce active immunotoxins with about 
the same activity. Furthermore, we have changed the order of 
the variable regions without affecting activity (Table I). Stim- 
ulated by the finding of Ward et al. (15) that a single variable 
region can bind antigen, we made a chimeric toxin composed 
of the Vn of anti-Tat fused to PE40, but found it to be 
inactive (data not shown). Apparently, Vn by itself does not 
have a high affinity for the p55 subunit. However, it may be 
possible to make active immunotoxins with single variable 
regions with selected antibodies. 
Anti-Tac(Fv)-PE40 has much greater activity on human 
cells than IL2-PE40, a molecule which also binds to the IL2 
receptor (Table II). There are several reasons that may ac- 
count for this difference which are related to the number of 
p55 subunits on the target cells and the relative affinities of 
the two ligands for ~55. Anti-Tat binds to ~55 with a Kd - 
10m9 M, whereas the affinity of IL2 for p55 is - 10m8 M (16). 
Only when p55 is associated with p75 is the affinity increased 
to -lo-” M. In MT-1 cells where there are 100,000 p55 
subunits and no p75 subunits, the IDso of anti-Tac(Fv)-PE40 
is Cl rig/ml and the IDbO of IL2-PE40 is >lOO rig/ml. This 
probably reflects the affinities of the two ligands. On HUT102 
cells, where there are many p55 subunits and a moderate 
number of p75 subunits, IL2-PE40 and anti-Tac(Fv)-PE40 
are about equally active. It has been shown previously that 
the high affinity IL2 receptor composed of p55 and p75 is 
rapidly internalized when occupied by IL2 (or anti-Tat), 
whereas the low affinity p55 receptor is internalized much 
more slowly (17). Nevertheless, it appears that this slow entry 
route is compensated for by the fact that there are many more 
p55 molecules than high affinity receptors on the surface of 
target cells and also because the binding of anti-Tat to these 
molecules is much stronger than the binding of IL2 to ~55. 
Anti-Tac(Fv)-PE40 is very active on HUT102 cells that 
express both the low and high affinity human IL2 receptor. 
Moreover, the fusion protein is also highly active on cells with 
moderate or low numbers of receptors (Table I). In a mixed 
lymphocyte (leukocyte) reaction, which is an in vitro model 
system for alloreactive responses, anti-Tac(Fv)-PE40 inhib- 
ited the protein synthesis of T-lymphoblasts very efficiently. 
It has been shown that IL2 receptor-bearing cells play a very 
crucial role in graft rejection and the administration of anti- 
IL2 receptor antibody prolongs allograft survival (18-20). We 
have earlier made a chimeric toxin containing IL2 and PE40, 
which is active on mouse IL2 receptor-bearing cells (8, 14) 
and has been shown to significantly prolong the survival of 
vascularized heart allografts in mice (21). However, IL2-PE40 
has low activity on human activated T cells. Anti-Tac(Fv)- 
PE40, being enormously more active, might prove to be a 
potent immunosuppressive agent in humans. 
Another objective of creating chimeric toxins is their poten- 
tial use as anti-tumor agents. Since anti-Tac(Fv)-PE40 ap- 
pears to be a very active protein in vitro, we performed several 
experiments to investigate its activity in vivo. The LDbo of 
anti-Tac(Fv)-PE40 in mice was determined to be between 10 
and 25 pg. The protein appears to be slightly more toxic than 
some other chimeric toxins produced in our laboratory (LDsO 
- 20-50 fig). However, because of the extremely high activity 
of anti-Tac(Fv)-PE40, it may not be required to use very high 
doses in vivo. Anti-Tac(Fv)-PE40 when injected intraperito- 
neally in mice shows a peak of activity in the blood after 2 h 
and detectable levels are present up to 8 h. 
In summary, anti-Tac(Fv)-PE40 is a chimeric toxin which 
has been shown to be extremely cytotoxic to IL2 receptor 
expressing cells in tissue culture and in mixed lymphocyte 
reaction. The agent warrants evaluation as an anti-tumor and 
immunosuppressive agent in humans. 
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